investigational therapies

Summary

Summary: Treatments which are undergoing clinical trials or for which there is insufficient evidence to determine their effects on health outcomes; coverage for such treatments is often denied by health insurers.

Top Publications

  1. ncbi Use of off-label drugs in cancer care again under review
    Edward Braud
    Springfield Clinic, Springfield, IL, USA
    ONS News 20:8. 2005
  2. ncbi Investigational therapies for metastatic thyroid carcinoma
    R Michael Tuttle
    Joan and Sanford I Weill Medical College of Cornell University, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Natl Compr Canc Netw 5:641-6. 2007
  3. ncbi Ethical framework for the use of sham procedures in clinical trials
    Sam Horng
    Department of Clinical Bioethics, National Institutes of Health, Bethesda, MD 20892 1156, USA
    Crit Care Med 31:S126-30. 2003
  4. ncbi Rethinking research ethics
    Rosamond Rhodes
    Mount Sinai School of Medicine
    Am J Bioeth 5:7-28. 2005
  5. ncbi Research versus innovation: real differences
    Haavi Morreim
    University of Tennessee Health Science Center, USA
    Am J Bioeth 5:42-3; author reply W15-8. 2005
  6. ncbi Ethical issues in fetal surgery research
    Frank A Chervenak
    Department of Obstetrics and Eynecology, The New York Presbyterian Hospital, Weill Medical College of Cornell University, 525 East 68th Street, J 130, New York, NY 10021, USA
    Best Pract Res Clin Anaesthesiol 18:221-30. 2004
  7. ncbi Third-party payers and the cost of biomedical research
    Ana S Iltis
    Center for Health Care Ethics, Saint Louis University, St Louis, MO, USA
    Kennedy Inst Ethics J 15:135-60. 2005
  8. ncbi Congressmen say military should have the right to informed consent
    Dennis M Maloney
    The Deem Corporation, P O Box 44069, Omaha, NE 68144, USA
    Hum Res Rep 20:9. 2005
  9. ncbi Ethics of innovative surgery: US surgeons' definitions, knowledge, and attitudes
    Angelique M Reitsma
    Center for Biomedical Ethics, University of Virginia, PO Box 800758, Charlottesville, VA 22908 0758, USA
    J Am Coll Surg 200:103-10. 2005
  10. pmc When is surgery research? Towards an operational definition of human research
    C E Margo
    Watson Clinic, Lakeland, Florida, USA
    J Med Ethics 27:40-3. 2001

Detail Information

Publications237 found, 100 shown here

  1. ncbi Use of off-label drugs in cancer care again under review
    Edward Braud
    Springfield Clinic, Springfield, IL, USA
    ONS News 20:8. 2005
  2. ncbi Investigational therapies for metastatic thyroid carcinoma
    R Michael Tuttle
    Joan and Sanford I Weill Medical College of Cornell University, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Natl Compr Canc Netw 5:641-6. 2007
    ..Given the dramatic increase in availability of thyroid cancer clinical trials, all patients with radioactive iodine-refractory, progressive metastatic thyroid cancer should be considered for inclusion in a novel therapy trial...
  3. ncbi Ethical framework for the use of sham procedures in clinical trials
    Sam Horng
    Department of Clinical Bioethics, National Institutes of Health, Bethesda, MD 20892 1156, USA
    Crit Care Med 31:S126-30. 2003
    ....
  4. ncbi Rethinking research ethics
    Rosamond Rhodes
    Mount Sinai School of Medicine
    Am J Bioeth 5:7-28. 2005
    ..These include: the primacy of informed consent, the protection of the vulnerable, the substitution of beneficence for research's social purpose, and the introduction of an untenable distinction between innovation and research...
  5. ncbi Research versus innovation: real differences
    Haavi Morreim
    University of Tennessee Health Science Center, USA
    Am J Bioeth 5:42-3; author reply W15-8. 2005
  6. ncbi Ethical issues in fetal surgery research
    Frank A Chervenak
    Department of Obstetrics and Eynecology, The New York Presbyterian Hospital, Weill Medical College of Cornell University, 525 East 68th Street, J 130, New York, NY 10021, USA
    Best Pract Res Clin Anaesthesiol 18:221-30. 2004
    ..We demonstrate the applicability of this framework to fetal surgery research for spina bifida, a common fetal anomaly...
  7. ncbi Third-party payers and the cost of biomedical research
    Ana S Iltis
    Center for Health Care Ethics, Saint Louis University, St Louis, MO, USA
    Kennedy Inst Ethics J 15:135-60. 2005
    ....
  8. ncbi Congressmen say military should have the right to informed consent
    Dennis M Maloney
    The Deem Corporation, P O Box 44069, Omaha, NE 68144, USA
    Hum Res Rep 20:9. 2005
  9. ncbi Ethics of innovative surgery: US surgeons' definitions, knowledge, and attitudes
    Angelique M Reitsma
    Center for Biomedical Ethics, University of Virginia, PO Box 800758, Charlottesville, VA 22908 0758, USA
    J Am Coll Surg 200:103-10. 2005
    ..Surgeons were also invited to self-report knowledge about current federal regulations guiding human subject research and rules for informed consent for and IRB review of clinical research...
  10. pmc When is surgery research? Towards an operational definition of human research
    C E Margo
    Watson Clinic, Lakeland, Florida, USA
    J Med Ethics 27:40-3. 2001
    ..Enforcing more rigid and less ambiguous guidelines of human research may curtail enrolment into some studies, but it will also protect patients from being used as subjects without their knowledge...
  11. ncbi Innovation to research: some transitional obstacles in critical care units
    Cynthiane J Morgenweck
    Center for the Study of Bioethics, Medical College of Wisconsin, Milwaukee 53226, USA
    Crit Care Med 31:S172-7. 2003
  12. ncbi Beyond informed consent: the therapeutic misconception and trust
    I de Melo-Martin
    Division of Medical Ethics, Department of Public Health, Weill Cornell Medical College, 411 E 69th Street, New York, NY, USA
    J Med Ethics 34:202-5. 2008
    ..We show that concerns about misplaced trust and exploitation of such trust are also relevant, and ought to be taken into account, when considering why the therapeutic misconception matters ethically...
  13. ncbi [Some recent ethical dilemmas in randomized controlled clinical trials]
    Jozsef Kovacs
    Semmelweis Egyetem Magatartástudományi Intézet, Bioetika Részleg, Budapest, Nagyvárad tér 4 1089
    Orv Hetil 149:1753-60. 2008
    ..method" in the Declaration of Helsinki 2000. The article makes an attempt to survey some of the lessons of these debates...
  14. ncbi Bioterrorism, biodefense, and biotechnology in the military: a comparative analysis of legal and ethical issues in the research, development, and use of biotechnological products on American and British soldiers
    Ashley R Melson
    The Berkeley Law Firm, PC, USA
    Albany Law J Sci Technol 14:E1-E44. 2004
  15. ncbi Is it time to rethink the expanded-access programs for HIV infection?
    Valerianna Amorosa
    University of Pennsylvania, Philadelphia, PA 19104, USA
    J Infect Dis 196:974-7. 2007
    ....
  16. ncbi Trauma nursing
    Linda Lapointe
    Directorate of Combat and Doctrine Development, USA
    J Trauma 62:S77. 2007
  17. ncbi Investigational test protocols must include informed consent
    Barbara Harty-Golder
    MLO Med Lab Obs 36:32. 2004
  18. ncbi Smallpox revisited?
    Michael J Selgelid
    University of the Witwatersrand, South Africa
    Am J Bioeth 3:W-IF 1. 2003
    ..e. secret). I conclude by recommending numerous future areas for ethics research related to the weaponization of smallpox...
  19. ncbi A traditional jewish approach to risky medical treatment
    Daniel Eisenberg
    Department of Radiology, Albert Einstein Medical Center, Philadelphia, Pennsylvania 19141, USA
    Cancer Invest 25:209-15. 2007
    ..The approach of Jewish law is valuable in formulating a generic approach to the area of risky medical treatments and is beneficial in understanding the choices that Jewish patients might make regarding their care...
  20. ncbi Multiple dietary antioxidants enhance the efficacy of standard and experimental cancer therapies and decrease their toxicity
    Kedar N Prasad
    Center for Vitamin and Cancer Research, Department of Radiology, University of Colorado Health Sciences Center, Denver 80262 0278, USA
    Integr Cancer Ther 3:310-22. 2004
    ..This review also discusses the reasons for the current debates regarding the use of antioxidants during radiation or chemotherapy...
  21. ncbi Factors affecting innovation in pediatric surgery: hospital type and appendectomies
    Deena J Chisolm
    Department of Pediatrics, The Ohio State University, College of Medicine and Columbus Children s Research Institute, Columbus, OH 43205, USA
    J Pediatr Surg 41:1809-13. 2006
    ..This study examines the patterns of LA using a national database, focusing on variations in care between children's and general hospitals...
  22. ncbi Top 10 health-care trends for 2003: rising demand, increasing revenues and innovative technologies
    Russell C Coile
    Russ Coiles Health Trends 15:1, 3-10. 2003
  23. ncbi The value of antihypertensive drugs: a perspective on medical innovation
    David M Cutler
    Department of Economics, Harvard University, Cambridge, Massachusetts, USA
    Health Aff (Millwood) 26:97-110. 2007
    ..More effective use of antihypertensive medication would have an impact on mortality akin to eliminating all deaths from medical errors or accidents...
  24. ncbi Access for the terminally ill to experimental medical innovations: a three-pronged threat
    Shira Bender
    University of Pennsylvania, USA
    Am J Bioeth 7:3-6. 2007
  25. ncbi Difficulties in performing clinical trials of antithrombotic therapy in neonates and children
    M Patricia Massicotte
    Paediatric Thrombosis, Stollery Children s Hospital, University of Alberta, Edmonton, Alberta, Canada
    Thromb Res 118:153-63. 2006
    ..Means for overcoming these challenges are also addressed...
  26. ncbi Research-related injury: problems and solutions
    Larry D Scott
    University of Texas Medical School at Houston, USA
    J Law Med Ethics 31:419-28. 2003
  27. ncbi The scientific establishment of a new therapeutic intervention for developmental conditions: practical and ethical principles
    Shinji Ijichi
    Institute for EGT, Nagahama Shinryojyo, 8 3 Nagahama, Shimokoshiki mura, Satsuma gun, 896 1411 Kagoshima, Japan
    Childs Nerv Syst 19:711-5. 2003
    ....
  28. ncbi Testing and estimation in flexible group sequential designs with adaptive treatment selection
    Martin Posch
    Section of Medical Statistics, Core Unit for Medical Statistics and Informatics, Medical University of Vienna, Spitalgasse 23, A 1090 Wien, Austria
    Stat Med 24:3697-714. 2005
    ..Also point estimation in adaptive trials is considered. The methodology is illustrated in a detailed example based on an actual planned study...
  29. ncbi An innovative approach to the care of patients on phase I and phase II clinical trials: the role of the experimental therapeutics nurse
    Claire Carlson
    The Children s Hospital of Philadelphia, USA
    J Pediatr Oncol Nurs 22:353-64. 2005
    ..The broader role of nursing in clinical trials, the multidisciplinary challenges of experimental therapies, and the development of an innovative approach to caring for patients on phase I/II studies are discussed...
  30. ncbi Should patients undergoing chemotherapy and radiotherapy be prescribed antioxidants?
    Ralph W Moss
    Cancer Communications, Lemont, Pennsylvania 16851, USA
    Integr Cancer Ther 5:63-82. 2006
    ..A blanket rejection of the concurrent use of antioxidants with chemotherapy is not justified by the preponderance of evidence at this time and serves neither the scientific community nor cancer patients...
  31. ncbi New investigational therapies for gastroesophageal reflux disease
    Joel E Richter
    Department of Medicine, Temple University School of Medicine, 3401 North Broad Street, 8th Floor, Parkinson Pavilion, Philadelphia, PA, 19140, USA
    Thorac Surg Clin 15:377-84. 2005
    ..Which of these drugs, if any, will be the new GERD drug for the millennium is unknown. There is no question, however, that improved drug treatments will parallel a better understanding of the complicated pathophysiology of GERD...
  32. ncbi The importance of preservation of the ethical principle of equipoise in the design of clinical trials: relative impact of the methodological quality domains on the treatment effect in randomized controlled trials
    Benjamin Djulbegovic
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Account Res 10:301-15. 2003
    ..We argue that an adequate control intervention can be selected if people designing a trial explicitly take into consideration the ethical principle of equipoise, also known as "the uncertainty principle."..
  33. doi Compassionate approval process for experimental gene-based products
    Gladice Wallraven
    J Clin Oncol 26:1899-900. 2008
  34. ncbi Advances in the treatment of breast cancer
    S Moulder
    Department of Breast Medical Oncology and Phase I Program, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Pharmacol Ther 83:26-36. 2008
    ....
  35. ncbi Ophtec iris reconstruction lens United States clinical trial phase I
    Marianne O Price
    Cornea Research Foundation of America, Indianapolis, Indiana, USA
    Ophthalmology 111:1847-52. 2004
    ..To determine the safety and efficacy of the Ophtec model 311 iris reconstruction lens for treatment of visual disturbances, such as glare or photophobia, related to partial or total absence of the human iris...
  36. ncbi [Traditional and translational medicine]
    Theophile Godfraind
    Laboratoire de Pharmacologie, Universite Catholique de Louvain, Avenue Hippocrate 54, UCL 5410 B1200 Bruxelles
    Bull Acad Natl Med 191:715-25; discussion 725-6. 2007
    ..The European program entitled 'The Innovative Medicines Initiative' could facilitate the translation of information from benchtop to bedside...
  37. ncbi FDA perspective on antivirals against biothreats: communicate early and often
    Rosemary Roberts
    US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Counter Terrorism and Emergency Coordination, 10903 New Hampshire Avenue, White Oak Campus, Silver Spring, MD 20993, United States
    Antiviral Res 78:60-3. 2008
    ..Efficient development of therapeutics against these agents requires collaborative efforts among industry, academia and federal agencies...
  38. ncbi Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors
    Michael D Jensen
    Endocrine Research Unit, Division of Endocrinology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Obesity (Silver Spring) 14:143S-149S. 2006
    ..g., acipimox, pioglitazone). Surgically implanted gastric pacemaker systems that modulate vagus nerve activity and delay gastric emptying are under study...
  39. ncbi [Limitations of pharmacoeconomics from a clinical-pharmacological point of view]
    Markus Muller
    Universitätsklinik für Klinische Pharmakologie, Medizinische Universität Wien, Wien, Osterreich
    Wien Med Wochenschr 156:619-21. 2006
    ..Moreover situations with (5) incremental, small benefit, (6) lack of precedents in case of innovations or (7) obvious "efficacy-effectiveness gaps" may pose challenges in the pricing decision process for pharmaceuticals...
  40. ncbi The risk-benefit balance in the United States: who decides?
    John Graham
    Frederick S Pardee RAND Graduate School, Santa Monica, California, USA
    Health Aff (Millwood) 26:625-35. 2007
    ..Our ultimate purpose is to urge the U.S. health policy community to develop a more consistent way of thinking about how risk-benefit decisions could be guided by general principles...
  41. ncbi The arthroscopic surgeon: cowboy and scientist. Presidential address
    Stephen S Burkhart
    Arthroscopy 19:678-83. 2003
  42. ncbi Medical self-defense, prohibited experimental therapies, and payment for organs
    Eugene Volokh
    UCLA School of Law, USA
    Harv Law Rev 120:1813-46. 2007
  43. ncbi Controversies in sepsis clinical trials: proceedings of a meeting of the International Sepsis Forum, Lausanne, Switzerland, September 29, 2001
    R Phillip Dellinger
    Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08854, USA
    J Crit Care 21:38-47. 2006
    ..Once a therapy is approved, adopting less stringent but still appropriate criteria for the use of that therapy in clinical practice may be appropriate...
  44. ncbi The thin line between malpractice and benefit determination
    Jack A Rovner
    Manag Care 12:31-2. 2003
  45. ncbi Imperatives
    Michael P Aronson
    Department of Obstetrics and Gynecology, University of Massachusetts Medical School, Worcester 01605 2982, USA
    Am J Obstet Gynecol 192:1483-7. 2005
  46. ncbi Current drug development portfolio for antimalarial therapies
    Giancarlo A Biagini
    Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK
    Curr Opin Pharmacol 5:473-8. 2005
    ..The management of this portfolio is being driven by MMV (Medicines for Malaria Venture), with a number of projects recently reaching the clinical end of this drug development pipeline...
  47. ncbi Access to clinical devices through nontraditional routes
    Robert J Klepinski
    Fredrikson and Byron, P A, Minneapolis, MN, USA
    Food Drug Law J 62:849-63. 2007
  48. ncbi Listen to all the voices: an advocate's perspective on early access to investigational therapies
    Musa Mayer
    Clin Trials 3:149-53. 2006
    ..The essay that follows is inspired by the need for other voices from the patient and advocacy communities to be heard in this debate...
  49. ncbi Can we afford innovation?
    Leon Morgenstern
    Cedars Sinai Medical Center, Los Angeles, California 90048, USA morgenstern cshs org
    Surg Innov 14:138-9. 2007
  50. ncbi Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials
    Steven Snapinn
    Amgen Inc, One Amgen Center Drive, 24 2 C, Thousand Oaks, CA 91320, USA
    Stat Med 27:382-91. 2008
    ....
  51. ncbi Don't avoid experimental treatments
    Eric E Shore
    Med Econ 84:30. 2007
  52. ncbi Therapeutic developments in peroxisome biogenesis disorders
    M C McGuinness
    Kennedy Krieger Institute, Room 400A, 707 North Broadway, Baltimore, MD 21205, USA
    Expert Opin Investig Drugs 9:1985-92. 2000
    ..Dietary supplementation and/or modification and pharmacological induction of peroxisomes as treatment strategies for PBD patients will be the subject of this review...
  53. ncbi Cisplatin overdose: toxicities and management
    Roger Y Tsang
    Department of Oncology, Division of Medical Oncology, Cross Cancer Institute and University of Alberta, Alberta, Canada
    Drug Saf 32:1109-22. 2009
    ....
  54. ncbi Pharmacotherapy for allergic rhinitis: a critical review of leukotriene receptor antagonists compared with other treatments
    Robert A Nathan
    University of Colorado Health Sciences Center, Denver, Colorado, USA
    Ann Allergy Asthma Immunol 90:182-90; quiz 190-1, 232. 2003
    To review the mechanisms and clinical efficacy of leukotriene receptor antagonists, which are investigational therapies for allergic rhinitis, compared with intranasal corticosteroids and nonsedating antihistamines, which are the most ..
  55. ncbi Experimental therapies in renal replacement: the effect of two different potassium acetate-free biofiltration protocols on striated muscle fibers
    Giuseppe Coppolino
    Department of Internal Medicine, University of Messina, Messina, Italy
    Ther Apher Dial 11:375-81. 2007
    ..AFB(K) can minimize the negative effects of standard AFB treatment on neuromuscular excitability, most likely through a more gentle variation of potassium levels during dialysis...
  56. ncbi The pathogenesis and treatment of pruritus and fatigue in patients with PBC
    E A Jones
    Department of Gastrointestinal and Liver Diseases, Academic Medical Center, Amsterdam, The Netherlands
    Eur J Gastroenterol Hepatol 11:623-31. 1999
    ....
  57. pmc A biological global positioning system: considerations for tracking stem cell behaviors in the whole body
    Shengwen Calvin Li
    Center for Neuroscience and Stem Cell Research, Children s Hospital of Orange County Research Institute, University of California Irvine, 455 South Main Street, Orange, CA 92868, USA
    Stem Cell Rev 6:317-33. 2010
    ..We then discuss an ideal procedure for labeling and tracking stem cells in vivo, finally, we present a novel imaging system based on our experiments...
  58. ncbi Outcome predictors in substance use disorders
    Domenic A Ciraulo
    Division of Psychiatry, Boston University School of Medicine, Doctor s Office Building, 720 Harrison Avenue, Suite 914, Boston, MA 02118, USA
    Psychiatr Clin North Am 26:381-409. 2003
    ..As the ability to subtype disorders based on meaningful biologic differences grows, it is anticipated that several relevant outcome predictors that are specific for pharmacotherapy will emerge...
  59. ncbi The millennium criteria for the diagnosis of atopic dermatitis
    J D Bos
    Department of Dermatology, Academic Medical Center, University of Amsterdam, The Netherlands
    Exp Dermatol 7:132-8. 1998
    ..For study purposes, we suggest that the mandatory and principal criteria are sufficient. They are now evaluated and validated in ongoing atopic dermatitis treatment studies...
  60. ncbi Final common pathway for tinnitus: theoretical and clinical implications of neuroanatomical substrates
    Abraham Shulman
    Martha Entenmann Tinnitus Research Center, Forest Hills, New York, USA
    Int Tinnitus J 15:5-50. 2009
    ....
  61. ncbi Induction therapy in pediatric renal transplant recipients: an overview
    Asha Moudgil
    Department of Nephrology, Children s National Medical Center, Washington, District of Columbia 20010, USA
    Paediatr Drugs 9:323-41. 2007
    ..Newer lymphocyte-depleting agents such as alemtuzumab may be better utilized in minimization regimens involving one or two oral maintenance immunosuppressive agents...
  62. ncbi Mesenchymal stem-cell transplantation for hypoxic-ischemic brain injury in neonatal rat model
    Jin A Lee
    Departments of Pediatrics, Seoul National University Boramae Hospital and Seoul National University College of Medicine, Seoul, South Korea
    Pediatr Res 67:42-6. 2010
    ..Neurologic performance was significantly impaired only on the cylinder test after HI (p = 0.034), and MSC transplants improved it (p = 0.010). These suggest MSC can be a candidate for the treatment of neonatal HIE...
  63. ncbi A novel model of murine mucopolysaccharidosis type VII due to an intracisternal a particle element transposition into the beta-glucuronidase gene: clinical and pathologic findings
    C Vogler
    Department of Pathology, The Edward A Doisy Department of Biochemistry and Molecular Biology, St Louis University School of Medicine, Missouri 63104, USA
    Pediatr Res 49:342-8. 2001
    ..This feature makes them extremely useful for testing intrauterine therapies...
  64. ncbi Cancer-induced cachexia: a guide for the oncologist
    Norleena Gullett
    Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, USA
    J Soc Integr Oncol 7:155-69. 2009
    ..Experimental therapies are also discussed, including nonsteroidal antiinflammatory drugs, tumor necrosis factor alpha antagonists, tetrahydrocannabinol, growth hormone, ghrelin, oxandrolone, and omega-3 fatty acids...
  65. ncbi Hyperoxaluria and systemic oxalosis: current therapy and future directions
    Amy E Bobrowski
    Feinberg School of Medicine, Northwestern University, Division of Kidney Diseases, Department of Pediatrics, Children s Memorial Hospital, 2300 Children s Plaza 37, Chicago, IL 60614, USA
    Expert Opin Pharmacother 7:1887-96. 2006
    ..Such approaches give hope for a future therapeutic cure for primary hyperoxaluria that includes correction of the underlying genetic defect without exposure to the life-long dangers associated with organ transplantation...
  66. ncbi The twitcher mouse: a model for Krabbe disease and for experimental therapies
    K Suzuki
    Department of Neurology, University of North Carolina School of Medicine, Chapel Hill 27599, USA
    Brain Pathol 5:249-58. 1995
    ..It is expected that this model will be useful for basic studies on treatment of this group of genetic disorders affecting the brain through transgenic and/or gene therapy approaches...
  67. ncbi New innovative therapies for benign prostatic hyperplasia: any advance?
    H Christoph Klingler
    Department of Urology, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Curr Opin Urol 13:11-5. 2003
    ..Not surprisingly, interest centres on either understanding of prostatic growth during ageing or on various medical or interventional treatments...
  68. ncbi Cellular and molecular basis of portal hypertension
    V Shah
    Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Clin Liver Dis 5:629-44. 2001
    ....
  69. ncbi Hepatic encephalopathy. Metabolic consequence of cirrhosis often is reversible
    S Abou-Assi
    Division of Gastroenterology, McGuire Veterans Affairs Medical Center and Virginia Commonwealth University School of Medicine, 1201 Broad Rock Rd, Richmond, VA 23249, USA
    Postgrad Med 109:52-4, 57-60, 63-5 passim. 2001
    ..However, future research will likely focus on the correction of alterations in neurotransmission. It is hoped that newer therapies will provide protection from the putative neurotoxins that cause secondary defects in neurotransmission...
  70. ncbi Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting
    F Roila
    S Maria Hospital, Terni, Italy
    Ann Oncol 20:1867-73. 2009
    ..The aim of the study was to detect a dose response...
  71. ncbi Placebo treatment in acute stroke trials : benefit or harm to patients?
    R Libman
    Departments of Neurology, Long Island Jewish Medical Center, Long Island Campus for the Albert Einstein College of Medicine, New Hyde Park, NY 11040, USA
    Stroke 31:355-7. 2000
    ..We sought to determine the effect on outcome of participating in a clinical stroke trial while being treated with placebo...
  72. ncbi Comparison of 6-hydroxydopamine-induced medial forebrain bundle and nigrostriatal terminal lesions in rats using a lateralised nose-poking task with low stimulus-response compatibility
    Eilis Dowd
    Brain Repair Group, School of Biosciences, Cardiff University, Cardiff CF10 3US, UK
    Behav Brain Res 165:181-6. 2005
    ....
  73. pmc Production of MPS VII mouse (Gus(tm(hE540A x mE536A)Sly)) doubly tolerant to human and mouse beta-glucuronidase
    Shunji Tomatsu
    Edward A Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St Louis, MO 63104, USA
    Hum Mol Genet 12:961-73. 2003
    ..Corrective gene therapy in this model should provide high enough levels of expression of normal GUS monomers to overcome the dominant negative effect of mutant monomers on newly synthesized GUS tetramers in most tissues...
  74. ncbi Bioequivalence of a novel high-dose oral formulation of alpha-dihydroergocryptine
    Christian de Mey
    ACPS Applied Clinical Pharmacology Services, Mainz Kastel, Germany
    Arzneimittelforschung 56:205-11. 2006
    ..232) and 1.07 (90% CI: 0.95 to 1.20 - CVm: 0.220). In view of important medical-ethical constraints not to expose an unreasonably high number of subjects, these findings could be accepted as a sufficient demonstration of bioequivalence...
  75. ncbi Chronic pruritus: targets, mechanisms and future therapies
    Esther Pogatzki-Zahn
    Department of Anesthesiology and Intensive Care, Competence Center for the Diagnostic and Therapy of Chronic Pruritus, University of Munster, Munster, Germany
    Drug News Perspect 21:541-51. 2008
    ..The present review aims to provide an overview of current neurophysiological and neurochemical therapeutic models in chronic pruritus...
  76. ncbi Second autologous transplantation for multiple myeloma patients relapsing after the first autograft -- a pilot study for the evaluation of experimental maintenance therapies. Report of the prospective non-randomized pilot study of the Czech Myeloma Group
    A Krivanova
    Department of Internal Medicine Hematooncology, University Hospital Brno, Czech Republic
    Onkologie 27:275-9. 2004
    ..High-dose chemotherapy followed by autologous stem cell transplantation (AT) is accepted as first-line therapy for patients with multiple myeloma (MM), with very good tolerance and low mortality (2-3%)...
  77. ncbi An orthotopic skull base model of malignant meningioma
    Gilson S Baia
    Brain Tumor Research Center, Department of Neurological Surgery, University of California, San Francisco, CA 94143, USA
    Brain Pathol 18:172-9. 2008
    ..Thus, we describe a malignant meningioma model system that will be useful for investigating the biology of meningiomas and for preclinical assessment of therapeutic agents...
  78. ncbi Hydroalcoholic human placental extract: skin pigmenting activity and gross chemical composition
    P Pal
    Department of Cellular Biochemistry, Indian Institute of Chemical Biology, Calcutta
    Int J Dermatol 34:61-6. 1995
    ..A hydroalcoholic human placental extract has been developed by us with pigmenting activity based on experimental therapies. Its chemical analysis was the primary objective of this study...
  79. ncbi Sickle cell anemia in the female patient
    Nathalie Dauphin-McKenzie
    Department of Obstetrics and Gynecology, University of Miami Jackson Memorial Hospital, Miami, Florida, USA
    Obstet Gynecol Surv 61:343-52. 2006
    ..Whether any of these new agents are safe in pregnancy has yet to be determined...
  80. ncbi Polypharmacy among patients attending an AIDS clinic: utilization of prescribed, unorthodox, and investigational treatments
    R M Greenblatt
    Department of Medicine, University of California, School of Medicine, San Francisco
    J Acquir Immune Defic Syndr 4:136-43. 1991
    ..Despite having decided to obtain care at a university-based clinic, many of the participants of this study also chose to receive unorthodox therapies and care from nonprimary medical providers.(ABSTRACT TRUNCATED AT 250 WORDS)..
  81. ncbi Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients
    Wilhelm H Schmitt
    Fifth Department of Medicine, University Hospital Mannheim of the University of Heidelberg, Mannheim, Germany
    Kidney Int 65:1440-8. 2004
    ..Anecdotal data suggest that antithymocyte globulin (ATG) may be a treatment option for these patients. We now describe 15 patients treated with ATG for refractory Wegener's granulomatosis...
  82. ncbi Investigational therapies in the treatment of obesity
    Marcio C Mancini
    Sao Paulo University, Obesity and Metabolic Syndrome Group of the Endocrinology and Metabology Service, Faculty of Medicine, Hospital das Clinicas, Sao Paulo, Brazil
    Expert Opin Investig Drugs 15:897-915. 2006
    ..These differing approaches are reviewed and commented on in this article...
  83. ncbi Generalized interstitial granuloma annulare--response to adalimumab
    Siegfried Werchau
    Department of Dermatology, University of Heidelberg, Heidelberg, Germany
    Int J Dermatol 49:457-60. 2010
    ..A foreign-body granuloma formation induced by an unknown inciting antigen is suspected. Generalized forms often coincides with recalcitrant progression and frustrated experimental therapies...
  84. ncbi Novel therapies for pemphigus vulgaris: an overview
    Oliver A Perez
    Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15232, USA
    Drugs Aging 26:833-46. 2009
    ..This review highlights the latest case reports and studies that employ established as well as new therapeutics in a novel way to treat this rare, but serious, disorder...
  85. pmc Reference drug programs: effectiveness and policy implications
    Sebastian Schneeweiss
    Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    Health Policy 81:17-28. 2007
    ..This paper summarizes the mechanism and rationale of RDPs, presents evidence of their economic effectiveness and clinical safety, and concludes with some practical implications of implementing RDP policies...
  86. ncbi Acute respiratory distress syndrome
    Michael P Mortelliti
    Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA
    Am Fam Physician 65:1823-30. 2002
    ..Many patients who survive ARDS have permanent, mild to moderate impairment of lung function. Quality of life after hospitalization with ARDS may be poorer than that in similar patients without ARDS...
  87. ncbi Inhibition of coxsackievirus B3 and related enteroviruses by antiviral short interfering RNA pools produced using phi6 RNA-dependent RNA polymerase
    Michaela Nygårdas
    Department of Virology, University of Turku, Kiinamyllynkatu 13, FIN 20520 Turku, Finland
    J Gen Virol 90:2468-73. 2009
    ..The phi6-siRNA pool also inhibited replication of other enterovirus B species, such as coxsackievirus B4 and coxsackievirus A9...
  88. ncbi Androgen receptors in prostate cancer
    Z Culig
    Department of Urology, University of Innsbruck, Anichstrasse 35, A 6020 Innsbruck, Austria
    Endocr Relat Cancer 9:155-70. 2002
    ..New experimental therapies for prostate cancer are aimed to down-regulate AR expression and to overcome difficulties which occur because of the acquisition of agonistic properties of commonly used antiandrogens...
  89. ncbi Clinical implications of chromosomal abnormalities in multiple myeloma
    Evangelos Terpos
    Department of Hematology, 251 General Airforce Hospital, Athens, Greece
    Leuk Lymphoma 47:803-14. 2006
    ..melphalan and autologous stem cell transplantation (ASCT), and should therefore be treated with more investigational therapies. Alternatively, eligible patients who do not have these poor risk factors are more likely to benefit ..
  90. pmc The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics
    Jeffrey J Olson
    Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA
    J Neurooncol 96:115-42. 2010
    What evidence is available regarding the emerging and investigational therapies for the treatment of metastatic brain tumors?
  91. ncbi Leptin-based glycopeptide induces weight loss and simultaneously restores fertility in animal models
    I Kovalszky
    1st Department of Pathology and Experimental Cancer Research, Semmelweis University Medical School, Budapest, Hungary
    Diabetes Obes Metab 12:393-402. 2010
    ..Our novel peptidomimetic was tested for efficacy and lack of resistance induction in rodent models of obesity and appetite reduction...
  92. pmc Experimental therapies in hypertrophic cardiomyopathy
    Ali J Marian
    Center for Cardiovascular Genetics, St Luke s Episcopal Hospital and Texas Heart Institute, Brown Foundation Institute of Molecular Medicine, The Unversity of Texas Health Science Center, Houston, TX 77030, USA
    J Cardiovasc Transl Res 2:483-92. 2009
    ....
  93. ncbi When innovative therapies make economic sense: economic analysis of enoxaparin versus unfractionated heparin in the ESSENCE trial--an overview. Efficacy and Safety of Subcutaneous in non-Q Wave Coronary Events
    D Mark
    Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Can J Cardiol 14:24E-27E. 1998
    ..04). Results suggested that enoxaparin therapy compared with standard UFH therapy improves key clinical outcomes and saves money in patients with acute coronary syndrome...
  94. pmc Survivin expression in tuberous sclerosis complex cells
    Stephana Carelli
    Laboratory of Pharmacology, Department of Medicine, Surgery and Dentistry, University of Milan, Polo H San Paolo, Milano, Italy
    Mol Med 13:166-77. 2007
    ..Future experimental therapies for TSC and LAM may result from the targeted inhibition of survivin, which may enhance sensitivity to TSC2 therapy...
  95. ncbi Hematopoietic engraftment of XLA bone marrow CD34(+) cells in NOG/SCID mice
    Thomas Moreau
    Institut Paoli Calmettes, Centre de Thérapie Cellulaire et Génique, Marseille, France
    Cytotherapy 11:198-205. 2009
    ....
  96. pmc Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy
    M A Lima
    Department of Neurology, Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, MA 02215, USA
    J Neurol Neurosurg Psychiatry 81:1288-91. 2010
    ..In absence of a specific treatment, immunotherapies aiming at boosting the cellular immune response against JCV may improve the prognosis of PML...
  97. ncbi Using historical lesion volume data in the design of a new phase II clinical trial in acute stroke
    John Whitehead
    Department of Mathematics and Statistics, Medical and Pharmaceutical Statistics Research Unit, Lancaster University, Lancaster, UK
    Stroke 40:1347-52. 2009
    ..We discuss the design and the appropriate sample size for phase II studies in stroke based on lesion volume...
  98. pmc Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects
    Chi Mu Chuang
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Biomed Sci 16:49. 2009
    ..Antigen-specific immunotherapy has emerged as a novel alternate therapy for advanced stage cancers, which may be employed in conjunction with conventional therapies...
  99. ncbi A survey of case reports and case series of therapeutic interventions in the Archives of Dermatology
    Joerg Albrecht
    Department of Medicine and Division of Dermatology, John Stroger Hospital of Cook County, Chicago, Illinois 60612, USA
    Int J Dermatol 48:592-7. 2009
    ..Case reports and case series are often the first line of clinical evidence in the medical literature and, until stronger evidence becomes available, are the only guidance to new therapies...
  100. pmc Key role of the GITR/GITRLigand pathway in the development of murine autoimmune diabetes: a potential therapeutic target
    Sylvaine You
    Universite Paris Descartes, Paris, France
    PLoS ONE 4:e7848. 2009
    ..In this study, we examined the role of GITR/GITRLigand interaction in the progression of autoimmune diabetes...
  101. ncbi Monitoring in situ dosimetry and protoporphyrin IX fluorescence photobleaching in the normal rat esophagus during 5-aminolevulinic acid photodynamic therapy
    I A Boere
    Laboratory of Experimental Surgery and Oncology Ee102c, Erasmus Medical Center, Dr Molenwaterplein 50, 3016 GH Rotterdam, The Netherlands
    Photochem Photobiol 78:271-7. 2003
    ..Non-responders did not show the rapid initial decay and had a significantly lower rate of photobleaching during the second phase of the decay (P = 0.012)...

Research Grants69

  1. A Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
    Steven Kawut; Fiscal Year: 2009
    ..We aim to investigate safe but innovative therapies which could remodel the pulmonary vasculature and improve outcomes in this currently incurable disease. ..
  2. DYNAMICS OF THE NEURONAL CYTOSKELETON IN AGING BRAIN
    Ralph A Nixon; Fiscal Year: 2013
    ..Defining the specific steps in this regulation will help to clarify mechanisms leading to major neurological diseases, including dementias, and will identify novel cellular targets for developing innovative therapies for these diseases. ..
  3. Peptide Therapy for Pulmonary Arterial Hypertension
    Jawaharlal M Patel; Fiscal Year: 2013
    ..Confirmation of the mechanism-based physiological approach for NO releasing PDE5 inhibitor function of this novel peptide in preclinical animal model is innovative for progression towards Phase I clinical trial for treatment of PH. ..
  4. Angiogenic tissue engineering to limit post-infarction ventricular remodeling
    Y Joseph Woo; Fiscal Year: 2012
    ....
  5. NICHD INTERNATIONAL & DOMESTIC PEDIATRIC &MATERNAL HIV STUDIES COORDINATING CTR
    CAROL NESEL; Fiscal Year: 2013
    ..The Data Coordinating Center will facilitate the research for the evaluation of investigational therapies, diagnostic techniques, prevention strategies, epidemiology and natural history of multiple aspects of ..
  6. Redox Determinants of Severe Asthma
    Serpil C Erzurum; Fiscal Year: 2010
    ..At the conclusion of this project, we anticipate that we will be able to identify severe asthma redox phenotypes and to begin to develop therapies specific to individual biochemical disturbances. ..
  7. Osteoclasts from pluripotent stem cells as vectors to modify bone marrow environm
    Hector L Aguila; Fiscal Year: 2010
    ..In addition, these techniques can be adapted for developing novel venues to control the metastasis and establishment of tumors into bone. ..
  8. Towards a Model of Fanconi Anemia
    BEVERLY JO TOROK STORB; Fiscal Year: 2010
    ..We plan to optimize the methods for culture, genetic manipulation, and transplantation of SSC in dogs, and to use this technology to set the stage for producing a canine model of Fanconi Anemia. ..
  9. Novel lysine deacetylase 6 Hsp domain inhibitors against AML
    CHUNG JEN JAMES CHOU; Fiscal Year: 2013
    ..We will determine the efficacy of our lead HDAC6 inhibitor candidates against AML, performing pharmacokinetic and dynamic studies on lead inhibitor candidates, and validate the inhibitor's ability to influence biomarkers in vivo. ..
  10. Lipoproteins and Microbial Immunity
    HOBART WHITAKER HARRIS; Fiscal Year: 2013
    ....
  11. SPORE in Lymphoma
    Richard Ambinder; Fiscal Year: 2009
    ..abstract_text> ..
  12. Angiotensin II, IGF-1 and Skeletal Muscle Atrophy
    Patrice Delafontaine; Fiscal Year: 2013
    ..These findings will allow development of innovative therapies to treat cachexia in chronic conditions in which the RAS is activated. ..
  13. Quorum sensing-dependent interactions with biofilms and innate immunity defenses
    Alexander R Horswill; Fiscal Year: 2012
    ..Our studies will advance the understanding of how S. aureus uses a cell-to-cell communication system to control the transition from a variety of lifestyle states into an invasive pathogen. ..
  14. Metastatic protein network in BRAFV600E positive human thyroid cancers
    Carmelo Nucera; Fiscal Year: 2013
    ....
  15. Insulin-Like Growth Factor-1 and Atherosclerosis
    Patrice Delafontaine; Fiscal Year: 2013
    ..These findings should allow development of innovative therapies targeted at reducing acute vascular events that are most often related to plaque instability. ..
  16. Allogeneic Human Mesenchymal Stem Cells for the Treatment of Acute Lung Injury
    Michael A Matthay; Fiscal Year: 2013
    ....
  17. Glioma Associated Macrophages Facilitate Local Immunosuppression
    Orin Bloch; Fiscal Year: 2010
    ..We believe that macrophages expressing B7-H1 protein will cause local T-cell death, and create an immunosuppressive environment. ..
  18. SOUTHWEST ONCOLOGY GROUP
    Gary E Goodman; Fiscal Year: 2013
    ..PSOC members are active in administrative and scientific activities and are dedicated to support the goals of the Southwest Oncology Group. ..
  19. Susceptibility Genes in Primary Sjogren's Sydrome
    KATHY L contact MOSER; Fiscal Year: 2010
    ..The resulting knowledge should generate novel opportunities for the development of improved diagnostic tools, biomarkers for monitoring disease, and innovative therapies for this complex disorder and other related autoimmune diseases. ..
  20. Mesenchymal Stem Cells for Treatment of Acute Lung Injury
    Jae Woo Lee; Fiscal Year: 2012
    ..Current treatment options remain primarily supportive with lung protective ventilation and fluid conservative strategy. Innovative therapies are needed. ..
  21. Rare Diseases Clinical Research Consortia (RDCRC) for the RDCR Network
    Mark L Batshaw; Fiscal Year: 2013
    ..abstract_text> ..
  22. Regulating Pathways and Fidelity of DNA Replication and Repair by Acetylation
    Lata Balakrishnan; Fiscal Year: 2013
    ..Enzymes regulating the protein modifications during DNA transactions can be used as novel targets to develop innovative therapies to prevent genome deterioration. ..
  23. Targeted delivery of TGFbeta blockade to diseased glomeruli
    Yufeng Huang; Fiscal Year: 2010
    ....
  24. Aging and ARM: Dark Adaptation Impairment
    Cynthia Owsley; Fiscal Year: 2012
    ..A prospective study is proposed to address this and related questions. ..
  25. Mechanisms Mediating Age-Related Impairments in Microvascular Collaterals
    STEVEN JEFFREY MILLER; Fiscal Year: 2012
    ..The objective of this project is to identify mechanisms by which the flow-mediated production of nitric oxide is inhibited in collateral arteries of aging animals. ..
  26. Development of Monoclonal Antibody (Mab) Biologics against Neonatal Candidiasis
    Jose L Lopez-Ribot; Fiscal Year: 2013
    ....
  27. Evaluation of HCC Response to Systemic Therapy with Quantitative MRI
    Bachir Taouli; Fiscal Year: 2013
    ..This will be a highly significant progress in HCC and liver diseases given the increased burden of HCC in this country, and would benefit a large number of Americans over the next decade. ..
  28. Selective Cytopheresis Therapy in Systemic Inflammatory Response Syndrome
    Deborah A Buffington; Fiscal Year: 2013
    ....
  29. Pathologically modified TDP-43 in neurodegenerative diseases
    TANIA FRANCE GENDRON; Fiscal Year: 2012
    ....
  30. Stem cell manipulation via HOX gene regulation
    Stephen G Emerson; Fiscal Year: 2010
    ..These experiments will describe in detail the role of NF-Y in the biology of hematopoietic stem cells, and will develop two experimental therapies based directly on the biology of NF-Y, for both HSC expansion and HSC differentiation. ..
  31. Use and Comparative Effectiveness of Innovative Therapies for Hepatocellular Carc
    Hanna K Sanoff; Fiscal Year: 2013
    ..Sanoff with an uncommon combination of skills in CE research and clinical trials. With her clinical expertise in hepatocellular carcinoma, she would be a unique position to further the research agenda of this deadly disease. ..
  32. Coronary Dysregulation Associated with Obesity
    Christine L Oltman; Fiscal Year: 2013
    ..With the global increase in type II diabetes and onset of obesity increasing in younger populations, the burden to deliver health care to these individuals will continue to increase. ..
  33. Regulation of Itch Scratching by Spinal GRP Receptors in Primates
    Mei Chuan Ko; Fiscal Year: 2013
    ..Collectively, these studies will develop vald animal models of itch, improve scientific knowledge of GRPR in primates, and advance the discovery of innovative therapies targeting the GRPR for the treatment of pruritus in humans. ..
  34. Mapping the Critical Epitopes of Ara h 2 and Ara h 6
    Stephen C Dreskin; Fiscal Year: 2013
    ..The future direction of this research is to fully develop these tools and bring them to clinical practice. ..
  35. Uncovering CD36-mediated oxidative and inflammatory pathways in progressive renal
    DARYL MIYOSHI OKAMURA; Fiscal Year: 2010
    ..Our studies on the cellular receptor CD36 and its ligand oxidized lipoprotein will shed new light in the progression of chronic kidney failure with hopes of developing new innovative therapies to alter its natural progression. ..
  36. UCLA SPOTRIAS CENTER APPLICATION RENEWAL-PROGRAM PROJECT
    Jeffrey L Saver; Fiscal Year: 2012
    ..A Career Development Program will train the next generation of translational scientists in neurovascular disease at the premedical, medical student, and fellowship level. ..
  37. Potential Therapeutic Applications of Ecto-Nucleotidases in Lithium-induced NDI
    Bellamkonda K Kishore; Fiscal Year: 2010
    ....
  38. Neuronal Regeneration of Stroked Brain with Perlecan Domain V
    GREGORY JAYE BIX; Fiscal Year: 2013
    ....
  39. Characterization of Pancreatic Disease in a Novel Porcine Cystic Fibrosis Model
    Aliye Uc; Fiscal Year: 2010
    ..The goal of this application is to fully characterize pancreatic involvement in our novel CF pig model and to better understand the pathophysiological mechanisms leading to PI in CF. ..
  40. 2011 Lysosomal Disease Gordon Research Conference
    STEVEN UPSHAW WALKLEY; Fiscal Year: 2011
    ....
  41. Developing the Anolis Lizard as a Model of Musculoskeletal Regeneration
    Kenro Kusumi; Fiscal Year: 2011
    ..These findings will help development of innovative therapies for regeneration and repair of cartilage and muscle. ..
  42. Adiponectin replacement Therapy for HAND?
    Annadora J Bruce-Keller; Fiscal Year: 2013
    ....
  43. Innovative therapies to elimate persistent HIV Infection
    David M Margolis; Fiscal Year: 2010
    ..Within the Integrated Program, we will facilitate the study of "anti-latency therapy" on cells from HIV infected patients, and in model systems to move towards reagents might be used in future efforts to clear HIV infection. ..
  44. 12/15-lipoxygenase, Insulin-like Growth Factor-1 and Atherosclerosis
    Sergiy Sukhanov; Fiscal Year: 2013
    ..In addition, I anticipate that identification of molecular mechanisms regulating 12/15-LOX expression will offer new targets for therapeutic intervention. ..
  45. Doppler Optical Frequency Domain Imaging Instrument
    Dai Fukumura; Fiscal Year: 2010
    ....
  46. Molecular mechanisms of adult neurogenesis following traumatic brain injury
    MICHELLE LEE THEUS; Fiscal Year: 2010
    ..Our ultimate goal is to devise novel experimental therapies to treat brain injury and improve recovery of function in patients who sustain head trauma using adult neural stem cells. ..
  47. TOWARDS A REFINED MOLECULAR RECURSIVE PARTITIONING ANALYSIS MODEL FOR GLIOBLASTOM
    WALTER JOHN contact CURRAN; Fiscal Year: 2010
    ..for various the prognostic groups of GBM against which the results from clinical trials involving investigational therapies can be compared, much like its decade's old RTOG RPA predecessor model...
  48. OSTEOCLASTS AND BONE CANCER
    Denis R Clohisy; Fiscal Year: 2013
    ..This aim is critically important, as it will help direct future design of osteoclast-specific gene delivery vectors, ensuring cell-type-specific expression and maximizing safety. ..
  49. Mucosal HIV and Immunobiology Center
    Phillip D Smith; Fiscal Year: 2012
    ..As a result of this synergy, in only 3 1/2 years the Center has doubled its membership and NIDDK Base Grant support for digestive disease research on the UAB campus. ..
  50. Immunobiology of Blood and Vascular Systems Training Program
    JACK J HAWIGER; Fiscal Year: 2013
    ....
  51. Impact of intermittent hypoxia on ventilatory drive and apnea severity
    JASON HAROLD MATEIKA; Fiscal Year: 2010
    ..This treatment could be particularly useful in individuals who suffer from mild or moderate forms of OSA when used in conjunction with other potential innovative therapies. ..
  52. The role of miR-211 and its target genes in melanoma development in humans.
    RANJAN JOSEPH PERERA; Fiscal Year: 2013
    ..The translational impact of ths study will be to improve early melanoma detection, to help predict the risk of melanoma, and to distinguish benign lesion and precancerous lesions. ..
  53. Advanced Anatomic and Functional Response Assessment in Lung Cancer
    Lawrence H Schwartz; Fiscal Year: 2011
    ..The same standards are used to gauge the effectiveness of investigational therapies in patients with lung cancer...
  54. Bioinformatics For Translational Spinal Cord Injury Research
    Adam R Ferguson; Fiscal Year: 2013
    ..This represents a new direction for the field of experimental SCI and we expect this approach to help define outcome metrics that are comparable across species, facilitating translational SCI research. ..
  55. Somatic genetic predictors of response to therapy in metastatic melanoma
    Katherine L Nathanson; Fiscal Year: 2011
    ..In order to identify patient subsets that are most likely to respond and those for which other investigational therapies may be of higher priority, biomarker analyses in the context of large-scale clinical trials are ..
  56. Immune Responses of the Epithelium in Chronic Rhinosinusitis with Polyps
    Andrew P Lane; Fiscal Year: 2013
    ..These studies will significantly advance current knowledge about CRSwNP and create an opportunity to develop innovative therapies for this debilitating and costly medical condition. ..
  57. Toxoplasma gondii GRA protein function
    David J Bzik; Fiscal Year: 2013
    ....
  58. Sideport Needle Array Technologies for Prioritizing Drugs for Cancer Patients
    James M Olson; Fiscal Year: 2012
    ..This personalized treatment approach will improve patient outcome and enhance the quality of care for millions of individuals that suffer from cancer. ..
  59. Hormones and Cognition Over the Lifespan
    MIRIAM T WEBER; Fiscal Year: 2013
    ..Secondary aims are to determine the risk factors of cognitive impairment in the MT and to determine if cognitive impairments during the MT are predictive of age-related cognitive decline. ..
  60. Acquisition of a Q-TOF Mass Spectrometer
    Wei Li; Fiscal Year: 2012
    ..These projects focus on small-molecule drug discovery and drug delivery in the areas of cancer, obesity, diabetes, radiation protection, radiation mitigation, bacteria inflection and inflammation diseases. ..
  61. Functional Implications of Caveolae-localized Myocardial sGC in Heart Failure
    EMILY JOY TSAI; Fiscal Year: 2013
    ....
  62. Effect of nicotine self-administration on endocannabinoids &related lipids
    MATTHEW WALLACE BUCZYNSKI; Fiscal Year: 2013
    ..A better understanding of these processes should lead to innovative therapies that have direct impact and clinical relevance for reducing nicotine use in addicted individuals. ..
  63. UNIVERSITY OF NEW MEXICO CANCER CENTER PLANNING GRANT
    Cheryl Willman; Fiscal Year: 2004
    ..abstract_text> ..
  64. MICROVASCULAR ABNORMALITIES IN SEPSIS
    Steven Hollenberg; Fiscal Year: 2002
    ....
  65. Analysis of Human B Cell Tolerance in Humanized Mice
    Roberta Pelanda; Fiscal Year: 2009
    ..These novel systems will also be amenable for testing novel potential therapeutics on patient cells. ..
  66. CLINICAL GENE THERAPY PROGRAM FOR THE TREATMENT OF AIDS
    Rafael Amado; Fiscal Year: 2002
    ..abstract_text> ..
  67. GLOBE CONSERVATION IN TRANSGENIC RETINOBLASTOMA
    Timothy Murray; Fiscal Year: 2006
    ..It is likely that results from these studies will contribute immediately to the care of children with this devastating ocular malignancy. [unreadable] [unreadable] [unreadable]..
  68. Targeted antigen receptor treatment of cancer
    David Scheinberg; Fiscal Year: 2009
    ....
  69. Novel therapy for treating Multiple Sclerosis
    KENNETH PILLER; Fiscal Year: 2009
    ..The successful expression of this novel formulation will allow testing for efficacy in treating Multiple Sclerosis. ..